Tag

Your search for Difficult-to-treat patients returned 20 results.


Hepatitis C RAVs are Not a Barrier to Retreatment

Study published in the journal Hepatology suggests that sofosbuvir plus peginterferon and ribavirin for 12 weeks is effective and safe in patients who have not achieved SVR with prior regimens of one or more direct-acting antiviral (DAA) agents plus peginterferon and ribavirin. High rates of SVR12 are achieved regardless of the presence of resistance associated ...

Read More


Dr. E Lebovics: Post-EASL 2015 HCV Interview

During our last interview, you mentioned that extending the use of all oral, interferon-free, hepatitis C regimens to special populations including those with decompensated cirrhosis, post-transplant, and renal failure is an area of great interest. We would like to hear your thoughts on relevant clinical data presented at The International Liver Congress™ 2015, ...

Read More


DAA HCV Regimen effective in pts with cirrhosis

Interferon free, direct acting antiviral HCV regimen ledipasvir-sofosbuvir with and without ribavirin is effective and well tolerated in adult patients with HCV genotype 1 and cirrhosis who have failed previous HCV therapy Chronically infected patients with cirrhosis, especially those who have failed previous hepatitis C therapy, achieve consistently lower rates ...

Read More


EASL Congress HCV Interview: Dr E. Lebovics

Regarding studies that are ongoing, what are you most excited about seeing at EASL? The results of which studies and what types of studies? Dr. Lebovics: Well, now that we are able to eliminate hepatitis C with all oral regimens in about 95% of standard patients, one area of great interest is extending our currently available regimens to special populations, ...

Read More


Treating hepatitis C in difficult-to-treat patients

Interferon-free treatment regimens are highly effective, well-tolerated, and enable clinicians to treat patients with hepatitis C who cannot be treated with interferon-based regimens. In a review article recently published in the journal Nature Reviews Gastroenterology & Hepatology, Peter Ferenci, MD, describes and assesses the application of interferon-free ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Gaglio

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G15 The Association of Sofosbuvir and Daclatasvir For Treating Severe Recurrence of HCV Infection After Liver Transplantation: Results From a Large French ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Lebovics

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Current agents in special populations Abstract G02 Ledipasvir/Sofosbuvir with Ribavirin is Safe And Efficacious in Decompensated and Post Liver Transplantation Patients ...

Read More


Grazoprevir + elbasvir for difficult to cure HCV

Grazoprevir plus elbasvir without ribavirin is effective in HCV genotype 1-infected populations that are difficult to cure with HCV therapy (patients with well compensated cirrhosis and null responder patients with or without well compensated cirrhosis) There is a high medical need for an interferon-free, all-oral, short-duration hepatitis C (HCV) therapy that is ...

Read More


Hepatitis C: topical and comprehensive seminar

The Lancet has published a topical and comprehensive seminar on hepatitis C The March 2015 issue of the Lancet contains an authoritative seminar on hepatitis C (Webster DP, et al. Lancet. 2015;385:1124-1135). The Lancet is one of the world's leading medical journals; an independent and authoritative voice in global medicine. Dr. Daniel Webster and colleagues' ...

Read More


Two DAA regimen effective in difficult to treat HCV

Regimen of two direct-acting oral antivirals appears effective in patients with difficult to treat HCV subgenotypes 1a and 2b Therapies for HCV genotype 1, 2, and 3 infection have traditionally been peginterferon (pegIFN)-based. PegIFN is associated with adverse events including influenza-like symptoms and depression. Many patients decline PegIFN therapy, and a ...

Read More